Kenneth Saag News Today

Kenneth Saag, MD, explores the clinical significance of a study demonstrating treatment with pegloticase leads to bone remodeling in patients with gout.

In osteoporosis, bones become brittle and fragile, putting them at high risk of fractures or breaks. These "fragility fractures" can cause pain, suffering, disability and even death, and patients have increased risks of repeat fractures.

The study, funded by the Patient-Centered Outcomes Research Institute, will compare two pathways of post-fracture patient care. The study, funded by the Patient-Centered Outcomes Research Institute, will compare two path...

The rheumatology month in review features studies exploring ways to enhance care, an increased risk of adverse COVID-19 outcomes, and pegloticase plus methotrexate co-therapy for gout treatment.

At the 12-month mark, response rate in patients with uncontrolled gout was significantly higher in those treated with pegloticase and concomitant methotrexate when compared with placebo.

At month 12, response rate was significantly higher in patients receiving pegloticase and methotrexate when compared with concomitant placebo.

While praising CMS’ 2023 Medicare Physician Fee Schedule for offering more flexibility, the American College of Rheumatology has submitted comments of concern over proposed reimbursement cuts to critical rheumatology services.In a comment letter to CMS dated Sept. 6, ACR stated it had concerns regarding a proposed 4.4% decrease — from $34.61 to $33.08 — to the calendar year 2023

Women of childbearing age report losing access to the arthritis medication methotrexate in states with abortion bans after the Supreme Court ruling.

Patients are reporting they are being denied medication they need for care since Roe v. Wade was overturned.

Phil Walter/Getty Images(NEW YORK) -- The Department of Health and Human Services announced it is investigating reports of women being denied vital medication